3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
5
Sarcoma
2
Other hematologic neoplasm
2
Tumor-Agnostic
1
Other solid neoplasm
1
Lymphoid
1
Conditions
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Magnetic Resonance Spectroscopy
15
Surgical Procedures, Operative
14
Radiotherapy
13
Blood Specimen Collection
13
Biopsy
13
atezolizumab
12
Gemcitabine
12
fludarabine
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
7
liposomal doxorubicin
5
abemaciclib
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
pemigatinib
×
Sarcoma
×
Clear all
NCT07434843
2026-05-22
PEMIGIST
Dana-Farber Cancer Institute
Phase 2
Recruiting
24 enrolled
NCT06389799
2025-08-28
PERELI
Lund University Hospital
Phase 2
Recruiting
33 enrolled